Icrucumab

From WikiMD.org
Jump to navigation Jump to search

Icrucumab

Icrucumab (pronounced as i-kru-cu-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a significant role in angiogenesis.

Etymology

The name "Icrucumab" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for therapeutic monoclonal antibodies. The prefix "I-" is used for the source of the antibody, in this case, it is a fully human antibody. The infix "-cru-" is not specifically defined in the IUPAC nomenclature, but it is likely related to the target or disease state. The suffix "-mab" is used for monoclonal antibodies.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight infection and disease.
  • Vascular endothelial growth factor receptor 2 (VEGFR-2): A protein that plays a critical role in angiogenesis and vasculogenesis.
  • Angiogenesis: The physiological process through which new blood vessels form from pre-existing vessels.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski